Get started
Author

Kirstin Thelen

Observed name: Thelen, Kirstin
Institution: Bayer (Germany)
OpenAlex ID: A5087606354
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial
2019 · Christoph Male, Anthonie W A Lensing, et al. · The Lancet Haematology · 348
Cytochrome P450-mediated metabolism in the human gut wall
2009 · Kirstin Thelen, Jennifer B Dressman · Journal of Pharmacy and Pharmacology · 342
Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, Part 1: Oral solutions
2011 · Kirstin Thelen, Katrin Coboeken, et al. · Journal of Pharmaceutical Sciences · 139
Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals
2016 · Jan-Frederik Schlender, Michaela Meyer, et al. · Clinical Pharmacokinetics · 118
PDF
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation
2020 · Guy Young, Anthonie W.A. Lensing, et al. · Journal of Thrombosis and Haemostasis · 92
PDF
Development of a Paediatric Population-Based Model of the Pharmacokinetics of Rivaroxaban
2013 · Stefan Willmann, Corina Becker, et al. · Clinical Pharmacokinetics · 87
PDF
Towards Quantitative Prediction of Oral Drug Absorption
2008 · Jennifer B Dressman, Kirstin Thelen, et al. · Clinical Pharmacokinetics · 82
Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies
2019 · Paul Monagle, Anthonie W A Lensing, et al. · The Lancet Haematology · 80
BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokinetics
2019 · Dirk Thomas, Kirstin Thelen, et al. · Research and Practice in Thrombosis and Haemostasis · 79
PDF
Mechanism-based prediction of particle size-dependent dissolution and absorption: Cilostazol pharmacokinetics in dogs
2010 · Stefan Willmann, Kirstin Thelen, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 78
Evolution of a Detailed Physiological Model to Simulate the Gastrointestinal Transit and Absorption Process in Humans, Part II: Extension to Describe Performance of Solid Dosage Forms
2011 · Kirstin Thelen, Katrin Coboeken, et al. · Journal of Pharmaceutical Sciences · 76
Development of a Physiologically-Based Pharmacokinetic Model for Preterm Neonates: Evaluation with In Vivo Data
2015 · Karina Claassen, Kirstin Thelen, et al. · Current Pharmaceutical Design · 75
Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®
2012 · Stefan Willmann, Kirstin Thelen, et al. · Journal of Pharmacy and Pharmacology · 64
Pharmacokinetics of rivaroxaban in children using physiologically based and population pharmacokinetic modelling: an EINSTEIN-Jr phase I study
2018 · Stefan Willmann, Kirstin Thelen, et al. · Thrombosis Journal · 55
PDF
A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis
2024 · Wolfgang C. Winkelmayer, Anthonie W.A. Lensing, et al. · Kidney International · 42
Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
2018 · Anthonie W. A. Lensing, Christoph Male, et al. · Thrombosis Journal · 41
PDF
Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study
2018 · Dagmar Kubitza, Stefan Willmann, et al. · Thrombosis Journal · 40
PDF
Evaluation of changes in oral drug absorption in preterm and term neonates for Biopharmaceutics Classification System (BCS) class I and II compounds
2015 · Amit A. Somani, Kirstin Thelen, et al. · British Journal of Clinical Pharmacology · 40
PDF
Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
2020 · Stefan Willmann, Katrin Coboeken, et al. · The Journal of Clinical Pharmacology · 38
PDF
Utilizing In Vitro and PBPK Tools to Link ADME Characteristics to Plasma Profiles: Case Example Nifedipine Immediate Release Formulation
2013 · Christian Wagner, Kirstin Thelen, et al. · Journal of Pharmaceutical Sciences · 33
PDF
Analysis of Nifedipine Absorption from Soft Gelatin Capsules Using PBPK Modeling and Biorelevant Dissolution Testing
2009 · Kirstin Thelen, Ekarat Jantratid, et al. · Journal of Pharmaceutical Sciences · 28
Whole-body physiologically based pharmacokinetic population modelling of oral drug administration: inter-individual variability of cimetidine absorption
2009 · Stefan Willmann, Andrea N Edginton, et al. · Journal of Pharmacy and Pharmacology · 28
An update on computational oral absorption simulation
2011 · Jennifer B Dressman, Kirstin Thelen, et al. · Expert Opinion on Drug Metabolism & Toxicology · 23
Anticoagulation in pediatric cancer–associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr
2022 · Joseph S. Palumbo, Anthonie W. A. Lensing, et al. · Blood Advances · 21
PDF
Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis
2018 · Anthony Chan, Anthonie W. A. Lensing, et al. · Thrombosis Journal · 20
PDF
Works count: 35
Citation count: 2,114
H-index: 23
I10-index: 27
Year
Topic
Type